Back to results
US 2014/0005209 A1Published application
Methods of Using Selective Chemotherapeutic Agents for Targeting Tumor Cells
AssigneesWayne State University, Duquesne University of the Holy Ghost
InventorsAleem Gangjee, Larry H. Matherly
Life of this patent
Estimating the term…
Abstract
A method for treating cancer tumors, particularly ovarian cancer tumors, is described, where fused cyclic pyrimidine having a cancer treating ability is selectively delivered to an FR expressing cancerous tumor.
Claims25
A method for inhibiting GARFTase in cancerous tumors of a patient comprising:
- a) providing a fused cyclic pyrimidine having the chemical formula:
- where n=5 or 6;
- b) selectively delivering the fused cyclic primidine alone to breast, endometrial, kidney, lung, mesothelioma, and brain cancerous tumors, where the fused cyclic pyrimidine due to the use of CH2 chains, where n=5 or 6, targets primarily FR-expressing cancerous tumors;
- and
- c) parsing of the fused cyclic pyrimidine into said cancerous tumors where the fused cyclic pyrimidine itself acts as a cancer treating agent and inhibits GARFTase within the tumors.
2 more elements
A method for inhibiting GARFTase in cancerous tumors comprising:
- a) providing a fused cyclic pyrimidine having a cytotoxic capability having the chemical formula:
- where n=5 or 6;
- b) selectively targeting a folate receptor alpha (FR-alpha) expressing breast, endometrial, kidney, lung, mesothelioma, and brain cancerous tumor, with said fused cyclic pyrimidine, wherein said cancerous tumor expresses a plurality of FR receptors;
- c) selectively delivering said fused cyclic pyrimidine to said cancerous tumor;
- d) passing of the fused cyclic pyrimidine into said cancerous tumor;
- e) retaining said fused cyclic pyrimidine in said cancerous tumor for a sufficient time for lysing of said cancerous tumor;
- and
- f) lysing of said cancerous tumor by said fused cyclic pyrimidine binding with said GARFTase to inhibit DNA replication of said cancerous tumor.
5 more elements
Dependencies are inferred from the claim text.